AstraZeneca PLC

XNYS

Last traded price · USD

$187.76

−0.66%Delayed

Delayed 15 minutes · Source: ViewTrade · 6 Nov 2026, 01:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: $190.00
Previous close: $189.01
Volume: 3.3M
Day's high: $192.65
Day's low: $187.61

In brief

AstraZeneca PLC is a US-listed company listed on the New York Stock Exchange, valued at about $291.20B.
Its shares closed at $189.01 on 4 Nov 2026, up 15.2% over the past year.
From India you can buy AZN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy AstraZeneca PLC (AZN) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole AZN share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade AZN options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Above its 50- and 200-day averages
The 4 Nov 2026 close of $189.01 was 14.1% above its 50-day average ($165.62) and 4.9% above its 200-day average ($180.17). It has closed above the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed below the 200-day on 9 Jul 2026, 83 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
P/E 2.0× its peers' median
Trailing P/E of 92.0 against a median of 45.0 across 6 peers named in its company record (range 29.7 to 120.3).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 5 Nov 2026
Ahead of SPY over 1 year
1 month: +19.2% (SPY −1.6%). 3 months: +17.0% (SPY −0.4%). 1 year: +15.2% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AZN, SPY · as of 4 Nov 2026
RSI(14) at 73.5, 70 or above
The 14-session relative strength index closed at 73.5 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
60% of the way up its 52-week range
Closed at $189.01 on 4 Nov 2026: 11.1% below the 52-week high of $212.71 (18 Feb 2026) and 23.2% above the low of $153.41 (3 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+19.2%

6 months+2.2%

1 year+15.2%

5 years+48.1%

Newswire

About

A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.

Website

Notable moves

October 1, 2025
+9.96%
April 4, 2025
−7.39%
July 3, 2023
−8.83%

AstraZeneca PLC

XNYS

Last traded price · USD

$187.76

−0.66%Delayed

Delayed 15 minutes · Source: ViewTrade · 6 Nov 2026, 01:21 IST · A quote does not mean the product is available to trade on your account.

Day's open: $190.00
Previous close: $189.01
Volume: 3.3M
Day's high: $192.65
Day's low: $187.61

In brief

AstraZeneca PLC is a US-listed company listed on the New York Stock Exchange, valued at about $291.20B.
Its shares closed at $189.01 on 4 Nov 2026, up 15.2% over the past year.
From India you can buy AZN in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy AstraZeneca PLC (AZN) shares from India?

Do I need the price of a whole AZN share to invest?

How much can I invest in US stocks in a year?

Can I trade AZN options or futures?

Insights

Quotes run fifteen minutes behind.

Above its 50- and 200-day averages
The 4 Nov 2026 close of $189.01 was 14.1% above its 50-day average ($165.62) and 4.9% above its 200-day average ($180.17). It has closed above the 200-day for 4 sessions, since 30 Oct 2026. The 50-day average crossed below the 200-day on 9 Jul 2026, 83 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
P/E 2.0× its peers' median
Trailing P/E of 92.0 against a median of 45.0 across 6 peers named in its company record (range 29.7 to 120.3).
Quote feed P/E (price ÷ trailing 12-month EPS); peers as named in the company record · as of 5 Nov 2026
Ahead of SPY over 1 year
1 month: +19.2% (SPY −1.6%). 3 months: +17.0% (SPY −0.4%). 1 year: +15.2% (SPY +13.6%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: AZN, SPY · as of 4 Nov 2026
RSI(14) at 73.5, 70 or above
The 14-session relative strength index closed at 73.5 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
60% of the way up its 52-week range
Closed at $189.01 on 4 Nov 2026: 11.1% below the 52-week high of $212.71 (18 Feb 2026) and 23.2% above the low of $153.41 (3 Aug 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+19.2%

6 months+2.2%

1 year+15.2%

5 years+48.1%

Newswire

About

Website

Notable moves

October 1, 2025
+9.96%
April 4, 2025
−7.39%
July 3, 2023
−8.83%

AstraZeneca PLC

AstraZeneca PLC in brief

Above its 50- and 200-day averages

P/E 2.0× its peers' median

Ahead of SPY over 1 year

RSI(14) at 73.5, 70 or above

60% of the way up its 52-week range

AstraZeneca PLC

AstraZeneca PLC in brief

Above its 50- and 200-day averages

P/E 2.0× its peers' median

Ahead of SPY over 1 year

RSI(14) at 73.5, 70 or above

60% of the way up its 52-week range